{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-001631","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.337067+00:00","generated_at":"2026-06-09T00:42:54.270226+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mirum Q3 revenue $47.7M, LIVMARLI sales up 106%; CHENODAL/CHOLBAM acquisition completed","bullets":["Q3 2023 total revenue $47.7M (up 154% YoY); LIVMARLI global net sales $38.7M, +106% vs Q3 2022.","Acquisition of CHENODAL and CHOLBAM closed Aug 31; contributed $9M in Q3 sales.","Positive Phase 3 RESTORE for CHENODAL in CTX; NDA filing expected H1 2024; sNDA for LIVMARLI in PFIC PDUFA March 13, 2024.","Cash and investments $306M; convertible debt $316.3M; pipeline catalysts: EMBARK data by year-end, volixibat data H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-001631","json":"https://secwatch.observer/filing/0001157523-23-001631.json","markdown":"https://secwatch.observer/filing/0001157523-23-001631.md","text":"https://secwatch.observer/filing/0001157523-23-001631.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000115752323001631/0001157523-23-001631-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000115752323001631/a53739737.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:42:54.270226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"86564a173f829379732f5a81bd1991bfed3f455e","claim":"Mirum Pharmaceuticals, Inc. reported third quarter 2023 results: revenue $47.7 million.","evidence_excerpt":"EXHIBIT 99.1 Exhibit 99.1 Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update - Third quarter 2023 total revenue of $47.7 million - Completed acquisition of CHENODAL® and CHOLBAM® - Announced positive Phase 3 RESTORE study results evaluating CHENODAL (chenodiol) in patients with CTX; NDA filing expected in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000115752323001631/0001157523-23-001631-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2023"},{"label":"Revenue","value":"$47.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}